Lowering Triglycerides: ANGPTL4 Inhibition Explained
- For three decades, lowering LDL cholesterol with statins has been a cornerstone in preventing atherosclerotic cardiovascular disease (ASCVD).
- Research indicates that elevated triglycerides and remnant cholesterol are critical, frequently enough overlooked, contributors to ASCVD risk.
- Future research will likely explore combination therapies and targeted interventions to manage triglycerides and remnant cholesterol, aiming to further reduce ASCVD risk beyond what statins alone can achieve.
Beyond LDL: Addressing residual Risk in ASCVD with Statin Therapy
For three decades, lowering LDL cholesterol with statins has been a cornerstone in preventing atherosclerotic cardiovascular disease (ASCVD). Though, medical professionals recognize that a significant residual risk persists even with effective statin treatment.
Research indicates that elevated triglycerides and remnant cholesterol are critical, frequently enough overlooked, contributors to ASCVD risk. Focusing solely on LDL cholesterol may not fully address the complexities of cardiovascular health.
What’s next
Future research will likely explore combination therapies and targeted interventions to manage triglycerides and remnant cholesterol, aiming to further reduce ASCVD risk beyond what statins alone can achieve. A more holistic approach to lipid management is anticipated.